Paper41007722
STING-Activating Nanoparticles Combined with PD-1/PD-L1 Blockade: A Synergistic Approach in Cancer Immunotherapy.
Bartusik-Aebisher D and 2 others. Biomedicines, 2025. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. STING-Activating Nanoparticles Combined with PD-1/PD-L1 Blockade: A Synergistic Approach in Cancer Immunotherapy. Papers, record 41007722. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007722
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- STING-Activating Nanoparticles Combined with PD-1/PD-L1 Blockade: A Synergistic Approach in Cancer Immunotherapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References132
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 2 | 39735733 | Challenges and Opportunities in Targeting the Complex Pancreatic Tumor Microenvironment. | JCO Oncol Adv | 2024 | https://conductscience.org/library/papers/39735733 | PubMed |
| 3 | 38999073 | Agonists and Inhibitors of the cGAS-STING Pathway. | Molecules | 2024 | https://conductscience.org/library/papers/38999073 | PubMed |
| 4 | 40086770 | AI-driven innovations in smart multifunctional nanocarriers for drug and gene delivery: A mini-review. | Crit Rev Oncol Hematol | 2025 | https://conductscience.org/library/papers/40086770 | PubMed |
| 5 | 40500702 | Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40500702 | PubMed |
| 6 | 33188827 | Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. | J Control Release | 2021 | https://conductscience.org/library/papers/33188827 | PubMed |
| 7 | 37607938 | Cholesterol removal improves performance of a model biomimetic system to co-deliver a photothermal agent and a STING agonist for cancer immunotherapy. | Nat Commun | 2023 | https://conductscience.org/library/papers/37607938 | PubMed |
| 8 | 40052211 | Mitigating Doxorubicin-Induced Cardiotoxicity and Enhancing Anti-Tumor Efficacy with a Metformin-Integrated Self-Assembled Nanomedicine. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40052211 | PubMed |
| 9 | 34716197 | Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/34716197 | PubMed |
| 10 | 37779919 | Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer. | Mater Today Bio | 2023 | https://conductscience.org/library/papers/37779919 | PubMed |
| 11 | 38660408 | RGD targeted magnetic ferrite nanoparticles enhance antitumor immunotherapeutic efficacy by activating STING signaling pathway. | iScience | 2024 | https://conductscience.org/library/papers/38660408 | PubMed |
| 12 | 36282874 | Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study. | Clin Cancer Res | 2023 | https://conductscience.org/library/papers/36282874 | PubMed |
| 13 | 40294811 | Mitochondria-targeted manganese-based mesoporous silica nanoplatforms trigger cGAS-STING activation and sensitize anti PD-L1 therapy in triple-negative breast cancer. | Acta Biomater | 2025 | https://conductscience.org/library/papers/40294811 | PubMed |
| 14 | 40190094 | Nanosized Shikonin Disrupts Tumor-Cell Mismatch Repair and Synergizes with Manganese to Sensitize Squamous Carcinoma to Immunotherapy. | ACS Nano | 2025 | https://conductscience.org/library/papers/40190094 | PubMed |
| 15 | 39747173 | Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. | Nat Commun | 2025 | https://conductscience.org/library/papers/39747173 | PubMed |
| 16 | 40415537 | Grapefruit Extracellular-Vesicle-Derived Nanodrug Loading Three-Functional Platinum(IV) Conjugates with Enhanced Targeting and TME Modulating Properties. | J Med Chem | 2025 | https://conductscience.org/library/papers/40415537 | PubMed |
| 17 | 38117852 | ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/38117852 | PubMed |
| 18 | 34207137 | Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. | J Pers Med | 2021 | https://conductscience.org/library/papers/34207137 | PubMed |
| 19 | 36510011 | The cGAS-STING pathway and cancer. | Nat Cancer | 2022 | https://conductscience.org/library/papers/36510011 | PubMed |
| 20 | 40126217 | Ultrasound-Responsive Nanobubbles for Breast Cancer: Synergistic Sonodynamic, Chemotherapy, and Immune Activation through the cGAS-STING Pathway. | ACS Appl Mater Interfaces | 2025 | https://conductscience.org/library/papers/40126217 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42738166 | Cancer Drug Delivery with Nanoparticles and Biomolecules: Stimuli-Responsive, Theranostic, and AI-Guided Approaches. | Materials (Basel) | 2026 | https://conductscience.org/library/papers/42738166 | PubMed |
| 42029811 | Silica based nanocarriers for combination immunotherapy targeting the tumor immune microenvironment. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42029811 | PubMed |
| 41638631 | Biomimetic and personalized nanovaccines in cancer immunotherapy: Design innovations, translational challenges, and future directions. | J Adv Res | 2026 | https://conductscience.org/library/papers/41638631 | PubMed |
| 41516128 | Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41516128 | PubMed |
| 41514360 | Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/41514360 | PubMed |
| 41501823 | Cell-type specific activation of the cGAS-STING pathway in tumor immunotherapy: mechanisms and therapeutic implications. | J Transl Med | 2026 | https://conductscience.org/library/papers/41501823 | PubMed |
| 41150783 | The Role of MALDI-TOF Mass Spectrometry in Photodynamic Therapy: From Photosensitizer Design to Clinical Applications. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41150783 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CGAS | 115004 | PubTator's text mining | https://conductscience.org/library/genes/115004 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| STING1 | 340061 | PubTator's text mining | https://conductscience.org/library/genes/340061 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007722
GET https://conductscience.org/api/papers/v1/41007722/references?page=2